Hepatitis Forums
Advanced Liver Disease Main Forums => Advanced Liver Disease => Topic started by: Hep Editors on May 04, 2018, 10:11:26 am
-
Cyramza (ramucirumab), which slows tumor growth by blocking blood vessel formation, increased overall survival and progression-free survival in liver cancer patients with a specific biomarker, according to Phase III study results announced this week by Eli Lilly and Company.
The findings come from the REACH-2 trial, which tested Cyramza as a second-line treatment for people with hepatocellular carcinoma (HCC) who had high levels of alpha-fetoprotein (AFP), a biomarker associated with poor prognosis. The new results have not yet been presented at a scientific conference or published in a medical journal.
Read more...
https://www.hepmag.com/article/cyramza-improves-survival-people-liver-cancer